The phase II Rare Oncology Agnostic Research (ROAR) clinical trial of dabrafenib plus trametinib in patients with BRAF V600E mutation-positive recurrent or refractory high-grade glioma (including GBM) and low-grade glioma constitutes part of a larger basket trial BRF117019 (NCT02034110), evaluating dabrafenib and trametinib combination therapy across multiple BRAF V600E-mutant tumors. Here, BRAF is linked to central nervous system cancer.